Skip to main content
. 2020 Mar 9;4(5):906–919. doi: 10.1182/bloodadvances.2019001188

Table 3.

Characteristics of patient samples used in ex vivo cytotoxicity experiments

Patient Sex Age, y Diagnosis Subtype Disease phase % blasts in the blood Cytogenetics
1 M 57 AML M5 Relapsed 64.2 Normal
2 F 77 AML M5 De novo 25.5 46,XX,del(7)(q22q32)[19]/46,XX[1]
3 M 80 AML M1 De novo 96 Not done
4 M 61 AML Not documented De novo 53 Not documented
5 M 65 AML Not documented De novo 80 Not documented
6 M 79 AML Not documented De novo 49 Not documented
7 M 49 AML Not documented De novo 78 inv(16)(p13.1q22) or t(16;6)(p13.1;q22); CBEB-MYH11 FLT3-ITD+
8 M 66 AML Not documented De novo 68.8 Not documented
9 F 65 AML M0 De novo 75.8 Normal
10 M 33 AML M5 De novo 59.4 46,XY,t(9;11)(p21;q23)[5]

Available patient data for the diseased patient samples used in Figures 4 and 6.

F, female; M, male.